Skip to main content
OpenTrials
Completed

NCT Number: NCT03330184

Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level

The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Gut microbiota may play an important role in patients with prediabetes. Berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent obtained before any trial-related activities.
  • Male or female between 18 and 70 years of old.
  • 19≤Body mass index(BMI)≤30kg/m^2.
  • No participate in any clinical trial at least 3 months.
  • Diagnosed impaired fasting glucose(IFG) and impaired glucose tolerance(IGT) or Diabetes.
  • In visit 1, 5.60mmol/L≤Fasting plasma glucose(FPG)<8.0mmol/L; in visit 2, 6.1≤FPG<8.0mmol/L or 7.8≤2-hour postprandial plasma glucose(2h-PPG) <17mmol/L.
  • Females in child-bearing period should be given birth control.
  • No severe disease about heart, lung and kidney.

Exclusion criteria

  • Type 1 diabetes
  • Diabetes patients with previously treated or untreated FPG ≥ 8 mmol/L or 2-h PPG ≥ 17 mmol/L;
  • Women of childbearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using adequate contraceptive methods.
  • Those who are allergic to study drugs
  • Unable to cooperate
  • Abnormal liver function, ALT and AST are more than 2 times of the normal upper limit
  • Renal injury, blood creatinine ≥133 µmol/L
  • Poor blood pressure control, systolic blood pressure SBP≥160mmHg and/or diastolic blood pressure DBP≥95mmHg
  • Patients with chronic gastrointestinal diseases (pancreatitis, inflammatory bowel disease) and history of intestinal surgery
  • Patients with severe heart disease, such as heart failure, unstable angina pectoris, acute myocardial infarction
  • Chronic hypoxic diseases such as emphysema, pulmonary heart disease
  • Having obvious diseases of the blood system
  • Persons with tumor diseases
  • Endocrine diseases, such as hyperthyroidism and hypercortisolism
  • Mental illness, abuse of alcohol, drugs or other substances
  • Persons with long-term oral or intravenous corticosteroid hormones therapy
  • Having stress conditions such as surgery, severe trauma, etc.

Treatment and study plan

Berberine Hydrochloride group

Drug

Bifidobacterium group

Drug

Berberine Hydrochloride and Bifidobacterium group

Drug

Placebo

Drug

Primary outcomes

  1. Change of absolute value of fasting plasma glucose (mmol/L)

    Time frame: baseline and week 16

    Fasting plasma glucose will be measured during oral glucose tolerance test (OGTT) by glucose oxidase method at baseline and week 16.

Secondary outcomes

  1. Change of absolute value of 2-hour postprandial plasma glucose (mmol/L)

    Time frame: baseline and week 16

    2-hour postprandial plasma glucose will be measured during OGTT by glucose oxidase method at baseline and week 16.

  2. Change of level of HbA1c (%)

    Time frame: baseline and week 16

    HbA1c will be tested in plasma by high-performance liquid chromatography at baseline and week 16.

  3. Change of level of systolic pressure (mmHg)

    Time frame: baseline and week 16

    Systolic pressure will be measured by mercurial sphygmomanometer using the standard methods at baseline and week 16.

  4. Change of level of diastolic pressure (mmHg)

    Time frame: baseline and week 16

    Diastolic pressure will be measured by mercurial sphygmomanometer using the standard methods at baseline and week 16.

  5. Change of level of serum total cholesterol (mmol/L)

    Time frame: baseline and week 16

    Serum total cholesterol will be measured by fully automatic biochemical analyser at baseline and week 16.

  6. Change of level of low-density lipoprotein cholesterol (mmol/L)

    Time frame: baseline and week 16

    Serum low-density lipoprotein cholesterol will be measured by fully automatic biochemical analyser at baseline and week 16.

  7. Change of level of high-density lipoprotein cholesterol (mmol/L)

    Time frame: baseline and week 16

    Serum high-density lipoprotein cholesterol will be measured by fully automatic biochemical analyser at baseline and week 16.

  8. Change of level of triglycerides (mmol/L)

    Time frame: baseline and week 16

    Serum triglycerides will be measured by fully automatic biochemical analyser at baseline and week 16.

  9. Change of absolute value of body weight (kg)

    Time frame: baseline and week 16

    Body weight will be measured by weighing scale using the standard methods at baseline and week 16.

  10. Change of absolute value of body mass index (BMI) (kg/m^2)

    Time frame: baseline and week 16

    Weight and height will be combined to report BMI in kg/m^2 at baseline and week 16.

  11. Change of level of homeostasis model assessment (HOMA) index

    Time frame: baseline and week 16

    Fasting serum insulin and fasting plasma glucose will be calculated for HOMA index at baseline and week 16.

  12. Change of level of insulin early-phase secretion index

    Time frame: baseline and week 16

    Fasting serum insulin and 30 min post serum insulin during OGTT will be calculated for early-phase secretion index at baseline and week 16 .

  13. Change of level of insulin late-phase secretion index

    Time frame: baseline and week 16

    Fasting serum insulin and 2-hour post serum insulin during OGTT will be calculated for late-phase secretion index at baseline and week 16 .

  14. Change of level of GLP-1(pmol/L)

    Time frame: baseline and week 16

    GLP-1 will be measured in serum by ELISA KIT at baseline and week 16.

  15. Change of abundances of gut microbiota (%)

    Time frame: baseline and week 16

    Fecal samples will be measured by metagenomic sequencing to obtain abundances of gut microbiota at baseline and week 16.

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Collaborators

  • Chang'An Hospital
  • Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Shaanxi Aerospace Hospital
  • Shangluo Central Hospital
  • Xi'an Central Hospital
  • Xi'an Gaoxin Hospital
  • Yan'an People's Hospital
  • Yan'an University Affiliated Hospital

Registry information

Official study title

Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Nov 6, 2017
Registry last updated
Mar 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.